Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,577.48
(
-0.71%
)
US TECH 100
23,562.85
(
-0.98%
)
Dow Jones
45,797.62
(
-0.92%
)
Brent Oil
107.51
(
0.87%
)
Bitcoin
69,325.58
(
-2.69%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 171434

Wednesday, 06/10/2015 2:12:30 PM

Wednesday, June 10, 2015 2:12:30 PM

Post# of 257259
MRK-Samsung/BIIB*—Phase-3 trials for Enbrel and Remicade FoBs met primary endpoint:

http://finance.yahoo.com/news/merck-samsung-bioepis-announce-pivotal-124600445.html

The five FoBs in this collaboration are:

• Enbrel [worldwide except US/EU/Japan]
• Remicade [worldwide except EU/Russia/Turkey]
• Humira [worldwide except EU/Russia/Turkey]
• Herceptin [worldwide]
• Lantus [worldwide]

Samsung Bioepis is conducting the trials in all of the above programs except Lantus, where MRK has the lead role.

*d/b/a Samsung Bioepis.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now